Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population

Tumor Biology

Volumn 37, Issue 2, 2016, Pages 2233-2242

  Wang, Yu Mei ^a   Li, Zhe Xuan ^a   Tang, Fu Bing ^a   Zhang, Yang ^a   Zhou, Tong ^a   Zhang, Lian ^a   Ma, Jun Ling ^a   You, Wei Cheng ^a   Pan, Kai Feng ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Gastric cancer; Genetic polymorphism; Helicobacter pylori; Interleukins; Precancerous gastric lesions

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 32; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 8; IL18RAP PROTEIN, HUMAN; IL32 PROTEIN, HUMAN; INTERLEUKIN 18 RECEPTOR BETA; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ADULT; ALLELE; ARTICLE; ATROPHIC GASTRITIS; BLOOD SAMPLING; CANCER RISK; CHINESE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK POPULATION; HUMAN; IL 10 GENE; IL 18RAP GENE; IL 1BETA GENE; IL 22 GENE; IL 32 GENE; IL 4R GENE; IL 8 GENE; INTESTINAL NEURONAL DYSPLASIA; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRECANCER; PRECANCEROUS GASTRIC LESION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; STOMACH LESION; UREA BREATH TEST; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLICATION; DNA MICROARRAY; GENETIC PREDISPOSITION; GENETICS; MICROBIOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HELICOBACTER INFECTIONS; HUMANS; INTERLEUKIN-18 RECEPTOR BETA SUBUNIT; INTERLEUKINS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS;

EID: 84941336384     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4022-x     Document Type: Article

References (51)

1. IARC: Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013.
2. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48:3554–60.
3. Peek Jr RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:28–37.
4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–86.
5. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974–83.
6. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488–92.
7. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8:887–99.
8. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.
9. Polk DB, Peek Jr RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10:403–14.
10. Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer. 2002;100:249–60.
11. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007;133:659–72.
12. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004;202:275–93.
13. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398–402.
14. Lu W, Pan K, Zhang L, Lin D, Miao X, You W. Genetic polymorphisms of interleukin (IL)-1b, IL-1rn, IL-8, IL-10 and tumor necrosis factor {alpha} and risk of gastric cancer in a Chinese population. Carcinogenesis. 2005;26:631–6.
15. Berkovic MC, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, Kapitanovic S. IL-2-330 T/G SNP and serum values-potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (gep-nets). J Mol Med (Berl). 2010;88:423–9.
16. Burada F, Angelescu C, Mitrut P, Ciurea T, Cruce M, Saftoiu A, et al. Interleukin-4 receptor -3223t→c polymorphism is associated with increased gastric adenocarcinoma risk. Can J Gastroenterol. 2012;26:532–6.
17. Berkovic MC, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, Kapitanovic S. Il-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETS). Exp Mol Pathol. 2007;83:474–9.
18. Walczak A, Przybylowska K, Trzcinski R, Sygut A, Dziki L, Dziki A, et al. Association of −1112 c/t promoter region polymorphism of the interleukin 13 gene with occurrence of colorectal cancer. Pol Przegl Chir. 2011;83:27–31.
19. Zhang T, Wang H. Variants of interleukin-16 associated with gastric cancer risk. Asian Pac J Cancer Prev. 2013;14:5269–73.
20. Zhernakova A, Festen EM, Franke L, Trynka G, van Diemen CC, Monsuur AJ, et al. Genetic analysis of innate immunity in Crohn’s disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet. 2008;82:1202–10.
21. Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control. 2010;21:1165–70.
22. Li M, Edamatsu H, Kitazawa R, Kitazawa S, Kataoka T. Phospholipase Cepsilon promotes intestinal tumorigenesis of Apc(Min/+) mice through augmentation of inflammation and angiogenesis. Carcinogenesis. 2009;30:1424–32.
23. Yin L, Li Y, Ren J, Kuwahara H, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 2003;278:35458–64.
24. Shi Y, Hu Z, Wu C, Dai J, Li H, Dong J, et al. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet. 2011;43:1215–8.
25. You WC, Zhang L, Gail MH, Chang YS, Liu WD, Ma JL, et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst. 2000;92:1607–12.
26. Pan KF, Formichella L, Zhang L, Zhang Y, Ma JL, Li ZX, et al. Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population. Int J Cancer. 2014;134:2118–25.
27. Zhang L, Blot WJ, You WC, Chang YS, Kneller RW, Jin ML, et al. Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev. 1996;5:627–30.
28. 13C urea breath test. Am J Gastroenterol. 1996;91:690–4.
29. You WC, Zhang L, Gail MH, Ma JL, Chang YS, Blot WJ, et al. Helicobacter pylori infection, garlic intake and precancerous lesions in a Chinese population at low risk of gastric cancer. Int J Epidemiol. 1998;27:941–4.
30. Pages F, Berger A, Lebel-Binay S, Zinzindohoue F, Danel C, Piqueras B, et al. Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol Lett. 2000;75:9–14.
31. Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem. 1998;273:29445–50.
32. Cheung H, Chen NJ, Cao Z, Ono N, Ohashi PS, Yeh WC. Accessory protein-like is essential for IL-18-mediated signaling. J Immunol. 2005;174:5351–7.
33. Babar M, Ryan AW, Anderson LA, Segurado R, Turner G, Murray LJ, et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma. Am J Gastroenterol. 2012;107:1331–41.
34. Hedl M, Zheng S, Abraham C. The IL18rap region disease polymorphism decreases IL-18rap/IL-18r1/IL-1r1 expression and signaling through innate receptor-initiated pathways. J Immunol. 2014;192:5924–32.
35. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22:131–42.
36. Ishigami S, Arigami T, Uchikado Y, Setoyama T, Kita Y, Sasaki K, et al. IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol. 2013;30:472.
37. Joosten LA, Heinhuis B, Netea MG, Dinarello CA. Novel insights into the biology of interleukin-32. Cell Mol Life Sci. 2013;70:3883–92.
38. Vivier E, Spits H, Cupedo T. Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol. 2009;9:229–34.
39. Zhang N, Pan HF, Ye DQ. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem. 2011;353:41–6.
40. Qin SY, Yang XW, Luo W, Chen M, Liu ZL, Su SB, Jiang HX: Association of interleukin 22 polymorphisms with gastric cancer risk. Tumour Biol 2014.
41. Chen JP, Wu MS, Kuo SH, Liao F. IL-22 negatively regulates helicobacter pylori-induced CCL20 expression in gastric epithelial cells. PLoS One. 2014;9, e97350.
42. Lim C, Savan R. The role of the IL-22/IL-22r1 axis in cancer. Cytokine Growth Factor Rev. 2014;25:257–71.
43. Center DM, Kornfeld H, Cruikshank WW. Interleukin 16 and its function as a CD4 ligand. Immunol Today. 1996;17:476–81.
44. Mathy NL, Scheuer W, Lanzendorfer M, Honold K, Ambrosius D, Norley S, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology. 2000;100:63–9.
45. Burkart KM, Barton SJ, Holloway JW, Yang IA, Cakebread JA, Cruikshank W, et al. Association of asthma with a functional promoter polymorphism in the IL16 gene. J Allergy Clin Immunol. 2006;117:86–91.
46. Xu LL, Song ZC, Shang K, Zhao LQ, Zhu ZS. Non-association of IL-16 rs4778889 T/C polymorphism with cancer risk in Asians: a meta-analysis. Asian Pac J Cancer Prev. 2014;15:803–5.
47. El-Omar EM. The importance of interleukin 1beta in Helicobacter pylori associated disease. Gut. 2001;48:743–7.
48. Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1b and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol. 2010;25:1604–17.
49. Hackstein H, Hecker M, Kruse S, Bohnert A, Ober C, Deichmann KA, et al. A novel polymorphism in the 5′ promoter region of the human interleukin-4 receptor alpha-chain gene is associated with decreased soluble interleukin-4 receptor protein levels. Immunogenetics. 2001;53:264–9.
50. Kato I, Canzian F, Franceschi S, Plummer M, van Doorn LJ, Lu Y, et al. Genetic polymorphisms in anti-inflammatory cytokine signaling and the prevalence of gastric precancerous lesions in Venezuela. Cancer Causes Control. 2006;17:1183–91.
51. Zeng HM, Pan KF, Zhang Y, Zhang L, Ma JL, Zhou T, et al. Genetic variants of toll-like receptor 2 and 5, Helicobacter pylori infection, and risk of gastric cancer and its precursors in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2011;20:2594–602.